Imatinib mesylate

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Progressive Gastrointestinal Stromal Tumor

Conditions

Progressive Gastrointestinal Stromal Tumor

Trial Timeline

Oct 1, 2006 → Nov 1, 2012

NCT ID

NCT00510354

About Imatinib mesylate

Imatinib mesylate is a approved stage product being developed by Novartis for Progressive Gastrointestinal Stromal Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT00510354. Target conditions include Progressive Gastrointestinal Stromal Tumor.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01742299	Approved	Active	Mar 26, 2013	Apr 21, 2033	GIST and CML
NCT00867113	Phase 2	Completed	Jul 22, 2009	Dec 20, 2016	Gastrointestinal Stromal Tumor (GIST)
NCT00732784	Phase 1	Completed	Nov 1, 2008	Dec 1, 2012	Healthy
NCT01172548	Phase 2	Completed	Aug 1, 2008	Mar 1, 2014	Gastrointestinal Stromal Tumors
NCT01483014	Phase 2	Completed	Jun 1, 2008	Jan 1, 2012	Gastrointestinal Stromal Tumors
NCT00684411	Phase 2	Completed	Jun 1, 2008	Oct 1, 2013	T Cell Non-Hodgkin Lymphoma
NCT01545427	Phase 2	Terminated	Apr 1, 2008	Dec 1, 2008	Scleroderma
NCT00479934	Phase 2	Completed	Dec 1, 2007	Dec 1, 2010	Scleroderma, Localized
NCT00677092	Phase 2	Completed	Dec 1, 2007	Jul 1, 2009	Nephrogenic Systemic Fibrosis
NCT00555581	Phase 2	Completed	Aug 1, 2007	Dec 1, 2011	Systemic Sclerosis
NCT00510354	Approved	Completed	Oct 1, 2006	Nov 1, 2012	Progressive Gastrointestinal Stromal Tumor
NCT00427583	Phase 2/3	Terminated	May 1, 2006	—	Malignant Peripheral Nerve Sheath Tumors
NCT00124748	Phase 3	Terminated	Jun 1, 2005	Nov 1, 2010	Leukemia, Myeloid, Chronic Phase
NCT00171899	Approved	Completed	Apr 1, 2005	Jun 1, 2007	Chronic Myelogenous Leukemia
NCT00171912	Phase 2	Completed	Sep 1, 2004	Jan 1, 2012	Hypereosinophilic Syndrome
NCT00171977	Approved	Completed	Jul 1, 2004	—	Gastrointestinal Stromal Tumors
NCT00171938	Phase 2	Terminated	Apr 1, 2004	Jun 1, 2006	Glioblastoma
NCT00154349	Phase 2	Completed	Oct 1, 2003	Feb 1, 2007	Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
NCT00237172	Phase 2	Completed	Sep 1, 2002	—	Gastrointestinal Stromal Tumors
NCT00171860	Phase 2	Terminated	Sep 1, 2002	—	Hypereosinophilic Syndrome

Competing Products

20 competing products in Progressive Gastrointestinal Stromal Tumor

See all competitors

Product	Company	Stage	Hype Score
AP01	Avalyn Pharmaceuticals	Phase 2	44
Enzalutamide + Placebo	Astellas Pharma	Phase 3	77
Enzalutamide	Astellas Pharma	Phase 2	52
dirucotide + Placebo	Eli Lilly	Phase 2/3	65
dirucotide	Eli Lilly	Phase 2/3	65
HRS-4357 injection + Enzalutamide；Abiraterone	Jiangsu Hengrui Medicine	Phase 3	77
ABBV-8E12 + Placebo solution for IV infusion on Day 15	AbbVie	Phase 2	52
Placebo + ABBV-8E12	AbbVie	Phase 2	52
ABBV-8E12	AbbVie	Phase 1	33
AZD4635 + Durvalumab + Cabazitaxel	AstraZeneca	Phase 2	52
antisense oligonucleotide + placebo	Novartis	Phase 1	33
Trametinib 2 mg	Novartis	Pre-clinical	23
Everolimus	Novartis	Phase 2	52
sunitinib + everolimus + chemotherapies recommended in france	Novartis	Pre-clinical	23
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)	Novartis	Phase 3	77
FTY720 + Placebo	Novartis	Phase 3	77
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273	Novartis	Approved	85
Mayzent	Novartis	Pre-clinical	23
BAF312 + Placebo	Novartis	Phase 3	77
Tulmimetostat DL1 QD + Tulmimetostat DL2 QD + Tulmimetostat DL3 QD + Tulmimetostat Doses 1 or 2 QD + Tulmimetostat RP2D QD + JSB462 Dose 1 QD + JSB462 Dose 2 QD + JSB462 QD + Standard of Care (SoC)	Novartis	Phase 1/2	41

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved